JPWO2020190768A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020190768A5 JPWO2020190768A5 JP2021555491A JP2021555491A JPWO2020190768A5 JP WO2020190768 A5 JPWO2020190768 A5 JP WO2020190768A5 JP 2021555491 A JP2021555491 A JP 2021555491A JP 2021555491 A JP2021555491 A JP 2021555491A JP WO2020190768 A5 JPWO2020190768 A5 JP WO2020190768A5
- Authority
- JP
- Japan
- Prior art keywords
- dsrna
- compound
- oligonucleotide
- independently
- rna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962819189P | 2019-03-15 | 2019-03-15 | |
| US62/819,189 | 2019-03-15 | ||
| US201962864797P | 2019-06-21 | 2019-06-21 | |
| US62/864,797 | 2019-06-21 | ||
| US201962951441P | 2019-12-20 | 2019-12-20 | |
| US62/951,441 | 2019-12-20 | ||
| PCT/US2020/022748 WO2020190768A1 (en) | 2019-03-15 | 2020-03-13 | Oligonucleotides for tissue specific apoe modulation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022525208A JP2022525208A (ja) | 2022-05-11 |
| JPWO2020190768A5 true JPWO2020190768A5 (sr) | 2023-03-17 |
Family
ID=72520528
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021555491A Pending JP2022525208A (ja) | 2019-03-15 | 2020-03-13 | 組織特異的なａｐｏｅ調節のためのオリゴヌクレオチド |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20200362341A1 (sr) |
| EP (1) | EP3937951A4 (sr) |
| JP (1) | JP2022525208A (sr) |
| CN (1) | CN113811311A (sr) |
| AU (1) | AU2020239987A1 (sr) |
| CA (1) | CA3133241A1 (sr) |
| WO (1) | WO2020190768A1 (sr) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021041247A1 (en) * | 2019-08-23 | 2021-03-04 | University Of Massachusetts | O-methyl rich fully stabilized oligonucleotides |
| CN115955972A (zh) * | 2020-04-27 | 2023-04-11 | 阿尔尼拉姆医药品有限公司 | 载脂蛋白E(APOE)iRNA剂组合物及其使用方法 |
| CN114716518A (zh) * | 2021-01-06 | 2022-07-08 | 圣诺制药公司 | 一种能够抑制pcsk9表达的分子构造及药物组合物 |
| CA3223577A1 (en) * | 2021-06-22 | 2022-12-29 | University Of Massachusetts | Oligonucleotides for ifn-.gamma. signaling pathway modulation |
| WO2023086777A1 (en) * | 2021-11-09 | 2023-05-19 | Children's National Medical Center | Targeting apoe enhances t-cell killing in cancer immunotherapy |
| WO2024073705A1 (en) * | 2022-09-30 | 2024-04-04 | University Of Massachusetts | Ocular delivery of oligonucleotides |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006507841A (ja) * | 2002-11-14 | 2006-03-09 | ダーマコン， インコーポレイテッド | 機能的ｓｉＲＮＡおよび超機能的ｓｉＲＮＡ |
| US20060257851A1 (en) * | 2002-11-26 | 2006-11-16 | Itzhak Bentwich | Bioinformatically detectable group of novel viral regulatory genes and uses thereof |
| EP1989307B1 (en) * | 2006-02-08 | 2012-08-08 | Quark Pharmaceuticals, Inc. | NOVEL TANDEM siRNAS |
| EP2293800B1 (en) * | 2008-06-06 | 2016-10-05 | Quark Pharmaceuticals, Inc. | Compositions and methods for treatment of ear disorders |
| CN106237345A (zh) * | 2009-05-06 | 2016-12-21 | 库尔纳公司 | 通过针对脂质转运和代谢基因的天然反义转录物的抑制治疗脂质转运和代谢基因相关疾病 |
| EP2960333B1 (en) * | 2009-08-27 | 2017-10-04 | Idera Pharmaceuticals, Inc. | Composition for inhibiting gene expression and uses thereof |
| US20150141320A1 (en) * | 2012-05-16 | 2015-05-21 | Rana Therapeutics, Inc. | Compositions and methods for modulating gene expression |
| US20150337030A1 (en) * | 2012-05-31 | 2015-11-26 | The Trustees Of Columbia University In The City Of New York | Methods to treat alzheimer's disease using apoe inhibitors |
| US20170334977A1 (en) * | 2014-10-20 | 2017-11-23 | The Brigham And Women's Hospital, Inc. | Targeting Apolipoprotein E (APOE) in Neurologic Disease |
| WO2017132669A1 (en) * | 2016-01-31 | 2017-08-03 | University Of Massachusetts | Branched oligonucleotides |
| WO2021133941A1 (en) * | 2019-12-23 | 2021-07-01 | University Of Massachusetts | Oligonucleotides for tissue specific gene expression modulation |
-
2020
- 2020-03-13 AU AU2020239987A patent/AU2020239987A1/en active Pending
- 2020-03-13 US US16/818,563 patent/US20200362341A1/en active Pending
- 2020-03-13 CN CN202080036085.2A patent/CN113811311A/zh active Pending
- 2020-03-13 JP JP2021555491A patent/JP2022525208A/ja active Pending
- 2020-03-13 CA CA3133241A patent/CA3133241A1/en active Pending
- 2020-03-13 EP EP20772940.1A patent/EP3937951A4/en active Pending
- 2020-03-13 WO PCT/US2020/022748 patent/WO2020190768A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10538763B2 (en) | Compounds and methods for modulation of DUX4 | |
| JP2018516091A5 (sr) | ||
| JP2019214587A5 (sr) | ||
| CN106983768B (zh) | 用于在对象中调节smn2剪接的组合物和方法 | |
| CA2866392C (en) | Methods for modulating tau expression for reducing seizure and modifying a neurodegenerative syndrome | |
| KR20080031164A (ko) | ＳＲ 단백질의 결합의 방해에 의해 그리고 이차 ＲＮＡ구조의 방해에 의한 ｐｒｅ－ｍＲＮＡ에서 엑손 인식의조절 | |
| JP2023539341A (ja) | Ｄｕｘ４阻害剤およびその使用方法 | |
| JP2022518929A (ja) | Ａｐｐの発現を低減するための化合物及び方法 | |
| JPWO2019181946A1 (ja) | 毒性が軽減した核酸 | |
| JP2022188237A (ja) | 転写プロセシングの調節のための化合物及び方法 | |
| JPWO2020190768A5 (sr) | ||
| WO2021157730A1 (ja) | 核酸医薬とその使用 | |
| JP6934695B2 (ja) | 核酸医薬とその使用 | |
| JPWO2020033899A5 (sr) | ||
| JPWO2020205605A5 (sr) | ||
| JPWO2020041769A5 (sr) | ||
| JPWO2021195307A5 (sr) | ||
| CA3132388A1 (en) | Compositions and methods for treating huntington's disease | |
| JPWO2021216556A5 (sr) | ||
| WO2022250050A1 (ja) | ｓｃｐＢＮＡ又はＡｍＮＡを含むヘテロ核酸 | |
| WO2023042876A1 (ja) | ２'－修飾ヌクレオシドを含むヘテロ核酸 | |
| WO2023022229A1 (ja) | モルホリノ核酸を含む修飾ヘテロ核酸 | |
| JP7208911B2 (ja) | 核酸分子発現の調節 | |
| WO2021070959A1 (ja) | 修飾ヘテロ核酸 | |
| Riasi et al. | Gene silencing method based on DNA |